{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:18:07Z","timestamp":1784675887004,"version":"3.55.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.1001\/jamainternmed.2022.1022","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T15:32:50Z","timestamp":1650295970000},"page":"603","source":"Crossref","is-referenced-by-count":36,"title":["Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance"],"prefix":"10.1001","volume":"182","author":[{"given":"Roy","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Section of General Medicine and the National Clinician Scholars Program, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale University School of Public Health, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary P.","family":"Gross","sequence":"additional","affiliation":[{"name":"Cancer Outcomes Public Policy and Effectiveness Research Center, Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"},{"name":"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"McWilliams","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of General Internal Medicine and Primary Care, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosh K. V.","family":"Sethi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Center for Surgery and Public Health, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Rathi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"ioi220013r3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions.","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"ioi220013r5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of injectable cancer drug costs after launch in the United States.","volume":"36","author":"Gordon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"ioi220013r8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1001\/jamaoncol.2017.5544","article-title":"Spending by commercial insurers on chemotherapy based on site of care, 2004-2014.","volume":"4","author":"Winn","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"ioi220013r12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJMp2033734","article-title":"The future of drug-pricing transparency.","volume":"384","author":"Feldman","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"ioi220013r15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamainternmed.2019.0914","article-title":"Comparison of hospitals affiliated with PPS-exempt cancer centers, other hospitals affiliated with NCI-designated cancer centers, and other hospitals that provide cancer care.","volume":"179","author":"Merkow","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"4","key":"ioi220013r16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1377\/hlthaff.2018.0112","article-title":"Changes in hospital utilization three years into Maryland\u2019s Global Budget Program for Rural Hospitals.","volume":"37","author":"Roberts","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"ioi220013r20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jama.2021.8535","article-title":"Payer-negotiated prices in the diagnosis and management of thyroid cancer in 2021.","volume":"326","author":"Xiao","year":"2021","journal-title":"JAMA"},{"key":"ioi220013r21","doi-asserted-by":"publisher","DOI":"10.1177\/01945998211049330","article-title":"Private payer\u2013negotiated prices for outpatient otolaryngologic surgery.","author":"Wang","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ioi220013r22","doi-asserted-by":"publisher","DOI":"10.1002\/alr.v12.5","article-title":"Private payer\u2013negotiated prices for FDA-approved biologic treatments for allergic diseases.","author":"Wang","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"ioi220013r23","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07398-4","article-title":"Payer-negotiated prices for telemedicine services.","author":"Wu","journal-title":"J Gen Intern Med"},{"issue":"1","key":"ioi220013r29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamainternmed.2021.6445","article-title":"Payer-specific negotiated prices for prescription drugs at top-performing US hospitals.","volume":"182","author":"Feldman","year":"2022","journal-title":"JAMA Intern Med"},{"key":"ioi220013r30","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-07237-y","article-title":"Factors associated with compliance to the hospital price transparency final rule: a national landscape study.","author":"Jiang","journal-title":"J Gen Intern Med"},{"issue":"9","key":"ioi220013r33","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009-2018.","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"ioi220013r34","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1377\/hlthaff.2014.0540","article-title":"The 340B Drug Discount Program: hospitals generate profits by expanding to reach more affluent communities.","volume":"33","author":"Conti","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"ioi220013r35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMsa1706475","article-title":"Consequences of the 340B Drug Pricing Program.","volume":"378","author":"Desai","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"ioi220013r37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jama.2020.26821","article-title":"Regulation of health care prices: the case for backstop price caps in commercial health care markets.","volume":"325","author":"Chernew","year":"2021","journal-title":"JAMA"},{"key":"ioi220013r40","doi-asserted-by":"publisher","first-page":"i788","DOI":"10.1136\/bmj.i788","article-title":"Overspending driven by oversized single dose vials of cancer drugs.","volume":"352","author":"Bach","year":"2016","journal-title":"BMJ"},{"key":"ioi220013r41","article-title":"Where are the high-price hospitals? with the transparency rule in effect, colonoscopy prices suggest they\u2019re all over the place.","author":"Jiang","journal-title":"Health Aff"},{"key":"ioi220013r1","unstructured":"The IQVIA Institute. Medicine spending and affordability in the US: understanding patients\u2019 costs for medicines. August 4, 2020. Accessed April 1, 2021. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/medicine-spending-and-affordability-in-the-us"},{"key":"ioi220013r2","unstructured":"President\u2019s Cancer Panel. Promoting value, affordability, and innovation in cancer drug treatment: a report to the President of the United States from the President\u2019s Cancer Panel.  2018. Accessed April 1, 2021. https:\/\/prescancerpanel.cancer.gov\/report\/drugvalue\/pdf\/PresCancerPanel_DrugValue_Mar2018.pdf"},{"key":"ioi220013r4","unstructured":"PhRMA. Follow the dollar part II.  2021. Accessed April 1, 2021. https:\/\/www.phrma.org\/resource-center\/Topics\/Cost-and-Value\/Follow-the-Dollar-Part-2"},{"key":"ioi220013r6","unstructured":"Magellan? RX Management. Medical pharmacy trend report. Eleventh ed. 2020. Accessed April 1, 2021. https:\/\/issuu.com\/magellanrx\/docs\/mptr20_050421_weboptimizedwithlinks"},{"key":"ioi220013r7","unstructured":"Fronstin? P, Roebuck? MC, Stuart? BC. Location, location, location: cost differences for oncology medicines based on site of treatment.  2020. Accessed April 1, 2021. https:\/\/www.ebri.org\/content\/cost-differences-for-oncology-medicines-based-on-site-of-treatment"},{"key":"ioi220013r9","unstructured":"The Moran Co. Hospital charges and reimbursement for drugs: 2019 update analysis of markups relative to acquisition cost.  2019. Accessed April 1, 2021. https:\/\/www.themorancompany.com\/wp-content\/uploads\/2019\/07\/Hospital-Charges-Report-July-2019.pdf"},{"key":"ioi220013r10","unstructured":"Silverman? E. How much? hospitals mark up some medicines by 250% on average. STAT.  January 20, 2021. Accessed April 1, 2021. https:\/\/www.statnews.com\/pharmalot\/2021\/01\/20\/hospitals-biosimilars-drug-prices\/"},{"key":"ioi220013r11","unstructured":"Community Oncology Alliance. Non-profit charity hospitals make \u201ca handsome profit\u201d on cancer drugs, new report says.  September 14, 2021. Accessed October 1, 2021. https:\/\/www.prnewswire.com\/news-releases\/non-profit-charity-hospitals-make-a-handsome-profit-on-cancer-drugs-new-report-says-301376558.html"},{"key":"ioi220013r13","unstructured":"Centers for Medicare and Medicaid Services. Medicare and Medicaid programs: CY 2020 hospital outpatient PPS policy changes and payment rates and ambulatory surgical center payment system policy changes and payment rates: price transparency requirements for hospitals to make standard charges public.  November 27, 2019. Accessed March 1, 2021. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2019-11-27\/pdf\/2019-24931.pdf"},{"key":"ioi220013r14","unstructured":"National Cancer Institute. NCI-designated cancer centers.  2019. Accessed April 1, 2021. https:\/\/www.cancer.gov\/research\/infrastructure\/cancer-centers"},{"key":"ioi220013r17","unstructured":"US Department of Health and Human Services. Office of Pharmacy Affairs 340B OPAIS. Accessed April 1, 2021. https:\/\/340bopais.hrsa.gov\/coveredentitysearch"},{"key":"ioi220013r18","unstructured":"Data.CMS.gov. Centers for Medicare & Medicaid Services. Medicare Part B drug spending by drug. January 7. 2022. Accessed April 1, 2021. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-b-spending-by-drug?"},{"key":"ioi220013r19","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-approved drugs.  2021. Accessed October 10, 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/"},{"key":"ioi220013r24","unstructured":"Centers for Medicare & Medicaid Services. 2021 ASP drug pricing files: October 2021 update. Accessed October 10, 2021. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2021-asp-drug-pricing-files"},{"key":"ioi220013r25","unstructured":"US Department of Health and Human Services. Medicare program: hospital outpatient prospective payment and ambulatory surgical center payment systems and quality reporting programs; new categories for hospital outpatient department prior authorization process; clinical laboratory fee schedule: labor. August 12, 2020. Accessed April 1, 2021. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2020-08-12\/pdf\/2020-17086.pdf"},{"key":"ioi220013r26","unstructured":"Centers for Medicare & Medicaid Services. CMS-1715-F.  November 15, 2019. Accessed April 1, 2021. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/PFS-Federal-Regulation-Notices-Items\/CMS-1715-F"},{"key":"ioi220013r27","unstructured":"Kliff? S, Katz? J. Hospitals and insurers didn\u2019t want you to see these prices. here\u2019s why. The New York Times. August 21, 2021. Accessed September 1, 2022.  https:\/\/www.nytimes.com\/interactive\/2021\/08\/22\/upshot\/hospital-prices.html"},{"key":"ioi220013r28","unstructured":"MedPAC. May 2015 report to the Congress: overview of the 340B Drug Pricing Program.  May 22, 2015. Accessed April 1, 2021. https:\/\/www.medpac.gov\/document\/http-www-medpac-gov-docs-default-source-reports-may-2015-report-to-the-congress-overview-of-the-340b-drug-pricing-program-pdf\/"},{"key":"ioi220013r31","unstructured":"Centers for Medicare & Medicaid Services. CMS OPPS\/ASC final rule increases price transparency, patient safety and access to quality care. November 2, 2021. Accessed February 1, 2022. https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-oppsasc-final-rule-increases-price-transparency-patient-safety-and-access-quality-care"},{"key":"ioi220013r32","unstructured":"Muoio? D. CMS issued over 300 warnings, but no fines, to hospitals falling short on price transparency last year. Fierce Healthcare. January 7, 2022. Accessed February 1, 2022. https:\/\/www.fiercehealthcare.com\/hospitals\/cms-has-issued-over-300-warnings-but-no-fines-to-hospitals-falling-short-price"},{"key":"ioi220013r36","unstructured":"Conti? RM, Nikpay? S, Gracia? G, Buntin? MB. Proposed reforms to the 340B Drug Discount Program. Health Affairs Forefront. March 7, 2018. Accessed March 15, 2022. https:\/\/www.healthaffairs.org\/do\/10.1377\/forefront.20180306.70004\/full\/"},{"key":"ioi220013r38","unstructured":"Stein? MW. Under pressure: oncology drug costs in the State of Maryland. Medical Group Management Association. September 18, 2018. Accessed October 10, 2021. https:\/\/www.mgma.com\/resources\/financial-management\/under-pressure-oncology-drug-costs-in-the-state"},{"key":"ioi220013r39","unstructured":"Center for Healthcare Quality and Payment Reform. Strengths and weaknesses of global budgets. Accessed October 10, 2021. https:\/\/ruralhospitals.chqpr.org\/Global_Budgets.html"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2791386\/jamainternal_xiao_2022_oi_220013_1654268165.86687.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T15:05:59Z","timestamp":1654527959000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2791386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2022.1022","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}